Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427031
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-19
Brief Title:
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Sponsor:
Taejoon Pharmaceutical Co Ltd
Organization:
Taejoon Pharmaceutical Co Ltd
Study Overview
Official Title:
A Multi-center Randomized Double-blinded Active Control Parallel Phase 3 Trial to Evaluate the Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with dry eye syndrome the test drugTJO-083 or the control drug is administered for 12 weeks and the corneal staining of each group would be evaluated The purpose of this clinical Study is to demonstrate that the test drug is not clinically inferior to the control drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None